Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

DARKP00L Aug. 22 at 3:48 PM

$GUTS this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

willyield Aug. 22 at 2:59 PM

$GUTS retail gamblers to sell and move on

1 · Reply

CarolinesGrippy Aug. 21 at 6:27 PM

$GUTS https://x.com/invadecanada/status/1958596059233665224?s=46 Go like and retweet my thread! I’m going to continue it later. I barely got into the meat but I need to get some work done.

0 · Reply

CarolinesGrippy Aug. 21 at 1:51 PM

$GUTS go look what $IVVD did in February of this year upon the release of positive data. We could easily 10x in September, especially if this memes given the backdrop of all the $NVO, $HIMS, $LLY drama that is dominating the discourse right now on social media.

0 · Reply

robbrenner2 Aug. 19 at 6:47 PM

$GUTS

0 · Reply

Smauk Aug. 18 at 9:28 PM

$GUTS This is going to be huge for people that get in at $1

0 · Reply

Newguy21 Aug. 15 at 8:00 PM

$GUTS This will be double next Monday, watch and see

1 · Reply

robbrenner2 Aug. 15 at 4:38 PM

$GUTS we break above 1.06 and we're going to close that first gap to 1.41! (Not financial advice, don't know what I'm talking about, just always wanted to say it).

0 · Reply

willyield Aug. 15 at 2:01 PM

$GUTS Immediate short term - not expecting much movement unless there is a renewed hype around GLP-1 / weight-loss alternatives and gets correlated to this stock

0 · Reply

VINCE_CARTER Aug. 15 at 5:02 AM

$ALT The shorts in ALT have horrendous track records in the speculative stocks in which they were short Anyone can buy some $AAPL or other big tech; afterall this is late stage capitalism But step out of the zeitgeist and they fail @Biorich @DavidT305 $NVAX $SRPT $COIN $GUTS Y'all fail on both long & short sides of trades Are you long or short $ALT?

1 · Reply

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 12 days ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 17 days ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 18 days ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 18 days ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 19 days ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 19 days ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jul 16, 2025, 10:13 AM EDT - 5 weeks ago

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 2 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 2 months ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 3 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 3 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 3 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 3 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 4 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 6 months ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 6 months ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 6 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 7 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 9 months ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 9 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 9 months ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 10 months ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 10 months ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 10 months ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 10 months ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 10 months ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 11 months ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

Jun 23, 2024, 1:30 PM EDT - 1 year ago

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's

May 20, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

May 13, 2024, 10:37 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:00 PM EDT - 1 year ago

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

May 8, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

May 7, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

Apr 30, 2024, 8:38 AM EDT - 1 year ago

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

DARKP00L Aug. 22 at 3:48 PM

$GUTS this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

willyield Aug. 22 at 2:59 PM

$GUTS retail gamblers to sell and move on

1 · Reply

CarolinesGrippy Aug. 21 at 6:27 PM

$GUTS https://x.com/invadecanada/status/1958596059233665224?s=46 Go like and retweet my thread! I’m going to continue it later. I barely got into the meat but I need to get some work done.

0 · Reply

CarolinesGrippy Aug. 21 at 1:51 PM

0 · Reply

robbrenner2 Aug. 19 at 6:47 PM

$GUTS

0 · Reply

Smauk Aug. 18 at 9:28 PM

$GUTS This is going to be huge for people that get in at $1

0 · Reply

Newguy21 Aug. 15 at 8:00 PM

$GUTS This will be double next Monday, watch and see

1 · Reply

robbrenner2 Aug. 15 at 4:38 PM

$GUTS we break above 1.06 and we're going to close that first gap to 1.41! (Not financial advice, don't know what I'm talking about, just always wanted to say it).

0 · Reply

willyield Aug. 15 at 2:01 PM

$GUTS Immediate short term - not expecting much movement unless there is a renewed hype around GLP-1 / weight-loss alternatives and gets correlated to this stock

0 · Reply

VINCE_CARTER Aug. 15 at 5:02 AM

1 · Reply

robbrenner2 Aug. 15 at 12:28 AM

0 · Reply

moneybagerz Aug. 14 at 8:34 PM

$GUTS found this because of Peter thiel being invested here. That’s usually a good sign and his avg is much higher. Feeling good about the $1 entry

1 · Reply

CarolinesGrippy Aug. 14 at 7:50 PM

$GUTS might drop a super thread on this ticker later tonight on X. I’m frankly shocked this is sitting at a buck. I think there’s 5-10x potential here in the shortterm and untold x potential in the longterm.

0 · Reply

Mike__Hawk Aug. 14 at 4:55 PM

$GUTS follow BioRich if you want to lose your money.

0 · Reply

JarvisFlow Aug. 14 at 4:28 PM

Canaccord Genuity updates rating for Fractyl Health ( $GUTS ) to Buy, target set at 12 → 6.

0 · Reply

robbrenner2 Aug. 14 at 12:17 PM

$GUTS "Buy" Rating with a $6 target price. https://www.investing.com/news/analyst-ratings/canaccord-genuity-lowers-fractyl-health-stock-price-target-to-6-from-12-93CH-4191886

1 · Reply

mortimerT Aug. 13 at 7:07 PM

$GUTS any company that announces supposedly good data and then does an offering at a 60% discount to the current stock price is not a good investment. That's what these clowns did with their trash drug. Unreal that anyone would put money into this garbage when they can hardly give their stock away.

2 · Reply

savage1 Aug. 13 at 3:05 PM

$GUTS sorry only had to scroll down one post lol....what a clown.

0 · Reply

savage1 Aug. 13 at 3:04 PM

$GUTS Is biorich still here telling people this is a good investment?

0 · Reply

BioRich Aug. 13 at 2:46 PM

$ALT For those interested in the next generation of the weight loss sector, $GUTS is presenting at conference in about an hour. Worth a look for those actually interested in the future of Weight loss treatments. And yes, from my understanding, this could be a blockbuster add-on to any GLP-1 or WL treatment on market or hoping to hit the market, like $ALT. https://wsw.com/webcast/canaccord108/register.aspx?conf=canaccord108&page=guts&url=https://wsw.com/webcast/canaccord108/guts/2555045

0 · Reply

robbrenner2 Aug. 13 at 1:46 PM

$GUTS https://www.ainvest.com/news/fractyl-health-strategic-positioning-post-glp-1-market-catalyst-driven-opportunity-2025-2026-2508/

0 · Reply

mortimerT Aug. 13 at 9:49 AM

$GUTS lol, I don't know how you arrived at that conclusion. All I meant was they could have gotten twice the amount in an offering if they played it right. I'm sure a buyout could be on the table at some point, but they proved last night they have a long, long way to go to prove any of their technology works. This is a company with bad business people and they look like they'll be making a lot of bad financial decisions.

0 · Reply

Market Cap	51.30M
Revenue (ttm)	90,000.00
Net Income (ttm)	-68.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76,322.22%
Debt to Equity Ratio	-1.65

Volume	1,384,500
Avg Vol	915,702
Day's Range	N/A - N/A
Shares Out	50.29M
Stochastic %K	64%
Beta	1.66
Analysts	Strong Sell
Price Target	$6.67